Wen‐Ming Chu
Impact in
- Cancer Research top 1%
- NF-κB Signaling Pathways
- Cancer-related molecular mechanisms research
- Immunology top 2%
- Immune Response and Inflammation
- Immune Cell Function and Interaction
- interferon and immune responses
Papers in
-
- Protein Kinase Regulation and GTPase Signaling 3
- PI3K/AKT/mTOR signaling in cancer 3
- Genomics, phytochemicals, and oxidative stress 3
- Immunology 13
- Immune Response and Inflammation 10
- Co-authors
- Michael Karin (2 shared papers)Zhiwei Li (2 shared papers)Yinsheng Wan (16 shared papers)Tom Deerinck (1 shared paper)Mark H. Ellisman (1 shared paper)Yinling Hu (1 shared paper)Mireille Delhase (1 shared paper)Randall S. Johnson (1 shared paper)
- Journals
- International Journal of Molecular Medicine (3 papers)The Journal of Immunology (3 papers)The FASEB Journal (3 papers)PLoS ONE (3 papers)The Journal of Experimental Medicine (2 papers)
- Partner nations
- United StatesChinaItaly
In The Last Decade
Wen‐Ming Chu
41 papers receiving 3.4k citations
Wen‐Ming Chu's Hit Papers
Peers
Comparison fields: 5 of 116
- Cancer Research 1.1k
- Immunology 952
- Geriatrics and Gerontology 80
- Dermatology 205
- Molecular Biology 1.6k
Countries citing papers authored by Wen‐Ming Chu
This map shows the geographic impact of Wen‐Ming Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wen‐Ming Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wen‐Ming Chu more than expected).
Fields of papers citing papers by Wen‐Ming Chu
This network shows the impact of papers produced by Wen‐Ming Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wen‐Ming Chu. The network helps show where Wen‐Ming Chu may publish in the future.
Co-authors
The 25 scholars most cited alongside Wen‐Ming Chu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The IKKβ Subunit of IκB Kinase (IKK) is Essential for Nuclear Factor κB Activation and Prevention of Apoptosis Hit paper breakdown → | 1999 | 821 |
| 2 | 2012 | 411 | |
| 3 | 2017 | 294 | |
| 4 | 2006 | 262 | |
| 5 | 2008 | 147 | |
| 6 | 2007 | 147 | |
| 7 | 2009 | 124 | |
| 8 | 2006 | 111 | |
| 9 | 2008 | 103 | |
| 10 | 2005 | 97 | |
| 11 | 2007 | 87 | |
| 12 | 2015 | 82 | |
| 13 | 2015 | 78 | |
| 14 | 2006 | 61 | |
| 15 | 2005 | 54 | |
| 16 | 2005 | 53 | |
| 17 | 2005 | 50 | |
| 18 | 2007 | 49 | |
| 19 | 2015 | 47 | |
| 20 | 2007 | 42 |
About Wen‐Ming Chu
Wen‐Ming Chu is a scholar working on Molecular Biology, Immunology, Cancer Research, Cell Biology and Oncology, having authored 44 papers that have together received 3.5k indexed citations. Recurring topics across this work include Immune Response and Inflammation (10 papers), NF-κB Signaling Pathways (7 papers), Cancer-related molecular mechanisms research (4 papers), Skin Protection and Aging (4 papers), Protein Kinase Regulation and GTPase Signaling (3 papers), Cytokine Signaling Pathways and Interactions (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Genomics, phytochemicals, and oxidative stress (3 papers). The work is most often cited by research in Cancer Research (1.1k citations), Immunology (952 citations), Geriatrics and Gerontology (80 citations), Dermatology (205 citations) and Molecular Biology (1.6k citations). Wen‐Ming Chu has collaborated with scholars based in United States, China and Italy. Frequent co-authors include Michael Karin, Zhiwei Li, Yinsheng Wan, Tom Deerinck, Mark H. Ellisman, Yinling Hu, Mireille Delhase, Randall S. Johnson, Cong Cao and Nicola Kouttab. Their work appears in journals such as International Journal of Molecular Medicine, The Journal of Immunology, The FASEB Journal, PLoS ONE and The Journal of Experimental Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.